ArticleInflammatory bowel diseases2019
Comparative Incidence of Inflammatory Bowel Disease in Different Age Groups in the United States.
Article in Inflammatory bowel diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Exposure to per- and polyfluoroalkyl substances and inflammatory bowel disease: review and meta-analysis.Journal of exposure science & environmental epidemiology · 2026Pooled it
- Association Between Inflammatory Bowel Disease in Women and the Fertility Marker Anti-Müllerian Hormone.Digestive diseases and sciences · 2026Article
- Efficacy of Second-Line Advanced Therapy in Patients with Crohn's Disease After Failure of a First Anti-TNF: A Descriptive Analysis.Journal of clinical medicine · 2026Article
- Clinical characteristics and prognostic differences between elderly-onset and adult-onset ulcerative colitis: a two-center retrospective cohort study.Frontiers in medicine · 2026Article
- Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003-2020.Alimentary pharmacology & therapeutics · 2026Article
- Rituximab in PR3-ANCA positive patients with moderately to severely active ulcerative colitis: a multicenter real-world pilot study.Frontiers in pharmacology · 2025Article
- Clinical trials and young adults with inflammatory bowel disease.Health care transitions · 2025Article
- Regional Trends in Inflammatory Bowel Disease-Related Mortality in the US from 1999 to 2022.Clinical and experimental gastroenterology · 2025Article
- Oral mucosal findings in ambulatory patients with inflammatory bowel disease.Brazilian oral research · 2025Article
- Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects.BMC microbiology · 2024Article
- [Asperosaponin VI alleviates TNBS-induced Crohn's disease-like colitis in mice by reducing intestinal epithelial cell apoptosis via inhibiting the PI3K/AKT/NF-κB signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Utility of four machine learning approaches for identifying ulcerative colitis and Crohn's disease.Heliyon · 2024Article
- Global patterns in the epidemiology, cancer risk, and surgical implications of inflammatory bowel disease.Gastroenterology report · 2024Review
- C-X-C Motif Chemokine 12 Was Identified as a Potential Gene Target in the Treatment of Crohn's Disease.International journal of general medicine · 2024Article
- Unlocking the Power of Physical Activity in Inflammatory Bowel Disease: A Comprehensive Review.Gastroenterology research and practice · 2024Review
- Article
- Disentangling the age-related manner in the associations between gut microbiome and women's health: a multi-cohort microbiome study.Gut microbes · 2023Article
- Vaccination Against Measles, Mumps, Rubella and Incident Inflammatory Bowel Disease in a National Cohort of Privately Insured Children.Inflammatory bowel diseases · 2023Article
- Increased number of children in households may protect against inflammatory bowel disease.Pediatric research · 2023Article
- Inflammatory Bowel Diseases Before and After 1990.Gastro hep advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundData on the incidence of inflammatory bowel disease (IBD) by age group are available in countries outside of the United States or localized populations within the United States. We aimed to estimate the incidence rates (IRs) of IBD by age group using a US multiregional data set.
methodsWe used the Optum Research Database to identify incident IBD patients with a disease-free interval of 1.5 years between 2005 and 2015. Overall and age-specific IRs were calculated for 4 different age groups: pediatric (0-17 years), young adult (18-25 years), adult (26-59 years), elderly (>60 years). Time trends of incidence were evaluated in each age group. Perianal phenotype (in Crohn's disease [CD]) was also compared.
resultsThe mean IR for the cohort (n = 60,247) from 2005 to 2015 was 37.5/100,000. The IR was highest in adult and elderly cohorts (36.4 and 36.7/100,000 respectively). In the adult and elderly groups, the IR for UC was higher than that for CD, whereas the opposite was true in the pediatric and young adult groups. The IR increased over the 10-year study period for all age groups (time trends P < 0.001). The elderly group had less perianal disease than the adult group (20.8 vs 22.3%, respectively; P < 0.05).
conclusionsIn one of the most comprehensive evaluations of the incidence of IBD in the United States, we found an incidence rate similar to those of other national populations. We also confirmed differences of specific IBD phenotypes based on age groups, with lower rates of perianal disease in the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.